VSV/NDV hybrid viruses for oncolytic therapy of cancer

1. A recombinant oncolytic virus,

comprising a vesicular stomatitis virus (VSV),

wherein glycoprotein (G protein) of VSV is deleted, and which comprises

a modified fusion protein (F protein) of Newcastle disease virus (NDV), and

the hemagglutinin neuraminidase (I-IN) protein of NDV.

2. The recombinant oncolytic virus of claim 1 , wherein the modified fusion protein (F protein) of NDV is a F3aa-modified F protein,

and/or wherein the modified fusion protein comprises at least one amino acid substitution in the protease cleavage site,

and/or wherein the G protein of VSV is replaced by the modified fusion protein and the HN protein of NDV.

3. The recombinant oncolytic virus of claim 1 , wherein the modified fusion protein (F protein) of NDV comprises the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 12,

and/or wherein the modified fusion protein (F protein) of NDV is encoded by a nucleotide sequence of SEQ ID NO: 9 or SEQ ID NO: 11,

and/or wherein the HN protein of NDV comprises the amino acid sequence of SEQ ID NO: 6,

and/or wherein the HN protein of NDV is encoded by a nucleotide sequence of SEQ ID NO: 5.

4. A nucleic acid encoding a recombinant oncolytic virus according to claim 1 .

5. A vector comprising a nucleic acid of claim 4 .

6. The nucleic acid of claim 4 , comprising the nucleotide sequence of SEQ ID NO: 13,

and/or comprising a nucleotide sequence coding for an amino acid sequence having SEQ ID NOs: 6, 12, and 14 to 17.

7. A pharmaceutical composition, comprising:

(i) the recombinant oncolytic virus of claim 1 or a nucleic acid encoding a recombinant oncolytic virus according to claim 1 ; and

(ii) pharmaceutically acceptable carrier(s) and/or excipient(s).

8. The pharmaceutical composition of claim 7 , further comprising one or more compounds selected from

chemotherapeutic agents,

radiotherapeutic agents,

tumor vaccines,

immune checkpoint inhibitors,

cell carrier systems,

small molecule inhibitors,

embolization agents, and

shielding polymers.

9. The pharmaceutical composition of claim 7 , formulated for delivery via, route selected from intravenous, intra-arterial,

intradermal, subcutaneous, intramuscular, intratumoral, intraosseous, intraperitoneal, intrathecal, epidural, intracardiac, intraarticular, intracavernous, intracerebral, intracerebroventricular and intravitreal.

10. A method for oncolytic therapy wherein said method comprises the step of administering a therapeutically effective amount of the recombinant oncolytic virus according to claim 1 or a nucleic acid encoding the recombinant oncolytic virus according to claim 1 , to a patient.

11. The method according to claim 10 , further comprising the step of administering one or more additional agents selected from

cell carrier systems,

immunotherapies,

and

standard tumor therapies,

to said patient.

12. A method of treatment of cancer comprising the step of

administering to a subject in need thereof a therapeutically effective amount of the recombinant oncolytic virus of claim 1 or a nucleic acid encoding the recombinant oncolytic virus according to claim 1 .

13. The method according to claim 11 , wherein the cell carrier system is selected from T cells, dendritic cells, NK cells, and mesenchymal stem cells; the immunotherapy is selected from tumor vaccines and immune checkpoint inhibitors; and the standard tumor therapy is selected from radiofrequency ablation, chemotherapy, embolization, and small molecule inhibitors.

14. The vector according to claim 5 , further comprising one or more reporter genes and/or genes to be delivered to a target cell or tissue.

15. The vector according to claim 14 , wherein the reporter gene is selected from HSV1-sr39TK, the sodium iodide symporter (NIS), somatostatin receptor 2 (SSTR2), luciferase, green fluorescence protein (GFP), lacZ, and tyrosinase; and the gene to be delivered to a target cell or tissue is selected from immune stimulating genes, immune checkpoint inhibitory antibodies, and tumor associated antigens (TAA).

16. The recombinant oncolytic virus of claim 1 , wherein the modified fusion protein (F protein) of NDV comprises an amino acid substitution at position L289.

17. The recombinant oncolytic virus of claim 16 , wherein the amino acid substitution is L289A.

18. The vector according to claim 5 , comprising the nucleotide sequence of SEQ ID NO: 13, and/or comprising a nucleotide sequence coding for an amino sequence having SEQ ID NOs: 6, 12, and 14 to 17.